Addition Therapeutics
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $100M
Overview
Stealth biotech developing targeted in vivo gene therapies for solid tumors.
Oncology
Technology Platform
Engineered viral vector platform with targeting domains designed for selective in vivo delivery of therapeutic genes to cancer cells.
Funding History
1Total raised:$100M
Grant$100M
Opportunities
Potential to revolutionize cancer treatment by creating effective, scalable, and administratively simple gene therapies for prevalent solid tumors.
Risk Factors
High scientific risk in achieving sufficient tumor-specific targeting and therapeutic gene expression in humans to drive efficacy without severe side effects.
Competitive Landscape
Competes with advanced cell therapies and oncolytic viruses, but its in vivo, off-the-shelf targeted approach could offer distinct advantages for solid tumors.